<DOC>
	<DOCNO>NCT00211029</DOCNO>
	<brief_summary>The purpose study record number participant chronic renal disease receive treatment epoetin alfa recombinant erythropoietins develop pure red cell aplasia ( PRCA , rare form anemia ) study period .</brief_summary>
	<brief_title>A Study Observe Number Patients Who Develop Pure Red Cell Aplasia ( PRCA , Rare Form Anemia ) While Receiving Epoetin Alfa Other Recombinant Erythropoietins</brief_title>
	<detailed_description>This prospective ( observation population sufficient number person sufficient number year generate incidence mortality rate subsequent selection study group ) , observational ( clinical study participant may receive diagnostic , therapeutic , types intervention , investigator assign participant specific intervention ) cohort study . Study specific information collect participant chronic renal disease receive recombinant erythropoietin treatment course follow 2 year participant receive intervention study . Upon enter study , information collect regard disease history recombinant erythropoietin treatment . Every 3 month thereafter , progress information collect , include recombinant erythropoietin treatment , number red blood cell presence sign pure red cell aplasia ( PRCA ) development . The result study combine similar study ( EPO-IMU-402 ) also collect blood sample observe number patient develop antibody erythropoietin . Participants discontinue erythropoietin follow additional 12 month time erythropoietin discontinue . Participants receive standard-of-care treatment chronic renal disease individual Investigators . Participants primarily observe prospectively PRCA . The study hypothesis data provide framework expansion patient population estimate incidence PRCA associate use epoetin alfa recombinant erythropoietins therapeutic indication .</detailed_description>
	<mesh_term>Red-Cell Aplasia , Pure</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Male female patient legal age give consent accord local standard Patients must receive receive treatment erythropoietin part preexist treatment plan chronic renal ( ) disease Physicians treat patient must agree advance document appearance pure red cell aplasia ( PRCA ) information detail case may report regulatory agency ( patient identification protect ) If require local ethic committee , patient must give consent permit collection deidentified personal data specific purpose study Patients unable complete future followup visit Patients enter study follow symptom pure red cell aplasia ( PRCA ) : Loss effectiveness erythropoietin low number immature red blood cell erythropoietin show blood test bone marrow examination Patients history PRCA loss effectiveness erythropoietin time enrollment study Patients whose anemia respond previous treatment erythropoietin Patients history antibody erythropoietin prior entering study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Anemia , Hemoglobin , Red Blood Cells , Epoetin alfa</keyword>
	<keyword>Epoetin</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>Red Cell Aplasia , Pure Red Cell Aplasia</keyword>
	<keyword>Chronic Renal Failure</keyword>
	<keyword>Kidney Failure</keyword>
</DOC>